Then, under a high-dose NMN treatment, we used the SIRT1 agonist CAY10602, SIRT1 inhibitor selisistat, AMPK agonist GSK621, and AMPK inhibitor dorsomorphin to treat the lung adenocarcinoma cells, and evaluated the NAMPT, SIRT1, p-AMPK, AMPK, p-ACC, and ACC protein expressions using Western blot analysis. Here, SIRT1 is linked to lung adenocarcinoma.